Starling Oncology, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Starling Oncology, Inc. (DFPH) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $1.48 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-03-12
- Starling Oncology, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-12-31 was $214.00K, a 89.74% decline year-over-year.
- Starling Oncology, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-09-30 was $2.05M, a 44.71% increase year-over-year.
- Starling Oncology, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-06-30 was $684.00K, a 90.99% decline year-over-year.
- Starling Oncology, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-03-31 was $99.00K, a 93.61% decline year-over-year.
- Starling Oncology, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $1.48M, a 51.56% decline from fiscal 2024.
- Starling Oncology, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $3.05M, a 72.52% decline from fiscal 2023.
- Starling Oncology, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $11.10M, a 63.97% decline from fiscal 2022.
- Starling Oncology, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $30.80M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.48M 10-K · filed 2026-03-12 | |||
| 2024-12-31 | $214.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $2.27M derived: sum of 2 quarters · filed 2026-03-12 | $2.95M derived: sum of 3 quarters · filed 2026-03-12 | $3.05M 10-K · filed 2026-03-12 |
| 2024-09-30 | $2.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $2.74M derived: sum of 2 quarters · filed 2024-11-13 | $2.83M 10-Q · filed 2024-11-13 | $4.92M derived: sum of 4 quarters · filed 2025-03-26 |
| 2024-06-30 | $684.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $783.00K 10-Q · filed 2024-08-13 | $2.87M derived: sum of 3 quarters · filed 2025-03-26 | $4.29M derived: sum of 4 quarters · filed 2025-03-26 |
| 2024-03-31 | $99.00K 10-Q · filed 2024-05-14 | $2.18M derived: sum of 2 quarters · filed 2025-03-26 | $3.60M derived: sum of 3 quarters · filed 2025-03-26 | $11.20M derived: sum of 4 quarters · filed 2025-03-26 |
| 2023-12-31 | $2.08M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $3.50M derived: sum of 2 quarters · filed 2025-03-26 | $11.10M derived: sum of 3 quarters · filed 2025-03-26 | $11.10M 10-K · filed 2025-03-26 |
| 2023-09-30 | $1.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $9.01M derived: sum of 2 quarters · filed 2024-11-13 | $9.01M 10-Q · filed 2024-11-13 | $11.89M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $7.59M 10-Q · filed 2023-08-09 | $7.59M 10-Q · filed 2024-08-13 | $10.47M derived: sum of 3 quarters · filed 2024-05-14 | $19.60M derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-03-31 | $1.55M 10-Q · filed 2024-05-14 | $2.88M derived: sum of 2 quarters · filed 2024-05-14 | $12.00M derived: sum of 3 quarters · filed 2024-05-14 | $12.75M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $1.33M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $10.45M derived: sum of 2 quarters · filed 2024-03-28 | $11.20M derived: sum of 3 quarters · filed 2024-03-28 | $30.80M 10-K · filed 2024-03-28 |
| 2022-09-30 | $9.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $9.87M derived: sum of 2 quarters · filed 2023-11-08 | $29.47M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $749.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $20.35M 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | $19.60M 10-Q · filed 2023-05-10 |